All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Ibrutinib Plus Rituximab Shows PFS Benefit Over Chemoimmunotherapy in Untreated MCL

October 10th 2025

Ibrutinib plus rituximab showed a progression-free survival benefit vs standard chemoimmunotherapy in older patients with untreated mantle cell lymphoma.

FDA Grants Orphan Drug Designation to Cintredekin Besudotox in Glioblastoma

October 10th 2025

The regulatory agency has granted orphan drug designation to cintredekin besudotox for the treatment of patients with glioblastoma.

Ulrich Named President-Elect of AACI

October 10th 2025

Neli Ulrich, PhD, MS, has been elected by the members of the Association of American Cancer Institutes to serve as vice president/president-elect of the AACI Board of Directors.

OST-HER2 Displays Potential OS Benefit in Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma

October 10th 2025

OST-HER2 produced a potential overall survival benefit at 2 years in recurrent, fully resected, pulmonary metastatic osteosarcoma.

OncLive Poll Results Reveal Most Anticipated GI Cancer Abstracts and Subtypes Ahead of ESMO 2025

October 10th 2025

See poll results highlighting the top gastrointestinal oncology abstracts and subtypes to watch at the 2025 ESMO Congress.

Poll Results Highlight Gynecologic Oncology Abstracts to Watch Ahead of ESMO 2025

October 10th 2025

See poll results highlighting the top gynecologic oncology abstracts and subtypes to watch at the 2025 ESMO Congress.

Fruquintinib Represents Viable Later-Line Option for mCRC As Access Expands for Patients

October 9th 2025

Kanwal P.S. Raghav, MBBS, MD, discusses the role of fruquintinib for the treatment of patients with later-line colorectal cancer.

MPN Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 9th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in myeloproliferative neoplasms.

Daratumumab/Lenalidomide With Limited Dexamethasone Displays Feasibility in Older/Frail Newly Diagnosed Myeloma

October 9th 2025

Daratumumab plus lenalidomide, with reduced exposure to dexamethasone, led to a PFS improvement in frail, newly diagnosed multiple myeloma.

Dana-Farber’s Philip J. Kranzusch, Ph.D., Receives 2025 Blavatnik National Award for Young Scientists

October 9th 2025

Philip J. Kranzusch, PhD, was one of three scientists awarded top honors at the 2025 Blavatnik National Awards for Young Scientists.

ONO-4578 Plus Nivolumab/Chemo Improves PFS in HER2– Advanced Gastric Cancer

October 9th 2025

ONO-4578 plus nivolumab and chemotherapy improved PFS in HER2-negative advanced gastric cancer.

FDA Grants Fast Track Designation to ADCE-D01 for Soft Tissue Sarcoma

October 9th 2025

The FDA granted fast track designation to ADCE-D01 for the treatment of soft tissue sarcoma.

ESMO 2025 Will See Novel Agents Emerge and Standard Strategies Shift in GI Oncology

October 9th 2025

Ahead of the 2025 ESMO Congress, GI cancer experts share the gastric cancer and CRC research they’re most looking forward to seeing at the meeting.

Poor Response Rates Persist After Progression on Brexu-Cel in Mantle Cell Lymphoma

October 9th 2025

Patients with MCL who relapsed after brexu-cel had poor survival outcomes, underscoring the need for effective post–CAR T-cell therapy strategies.

Eribulin Plus Pyrotinib Displays Efficacy in Trastuzumab-Resistant HER2+ Breast Cancer

October 9th 2025

Eribulin with pyrotinib was safe and active in patients with HER2-positive advanced breast cancer who were resistant to treatment with trastuzumab.

Urothelial Cancer Monthly Rewind: Key News and Expert Insights You May Have Missed in September 2025

October 8th 2025

Check out this September recap of OncLive’s coverage of the top news and expert insights in urothelial cancer.

FDA Approves Adjuvant Cemiplimab for Cutaneous Squamous Cell Carcinoma

October 8th 2025

The FDA approved cemiplimab-rwlc for the adjuvant treatment of cutaneous squamous cell carcinoma at high risk of recurrence after surgery and radiation.

Inside the Most Anticipated Genitourinary Cancer Abstracts: What to Watch at ESMO 2025

October 8th 2025

Experts in genitourinary oncology share key insights on the most anticipated data and abstracts expected to shape discussions at the 2025 ESMO Congress.

WTX-124 Nets FDA Fast Track Designation in Melanoma Following Immunotherapy

October 8th 2025

WTX-124 has received fast track designation from the FDA for locally advanced or metastatic cutaneous melanoma after standard-of-care immunotherapy.

FDA Grants Fast Track Designation to VT3989 for Unresectable Mesothelioma

October 8th 2025

VT3989 has received fast track designation from the FDA for unresectable malignant nonpleural or pleural mesothelioma after progression on prior therapy.